- Biocon Q4 FY26 Total Income at Rs 4,569 Cr
- EBITDA at Rs 1,073 Cr; Net Profit (before exceptional items) at Rs 179 Cr
- FY26 Total Income at Rs 17,270 Cr; EBITDA at
- Rs 3,798 Cr; Net Profit (before exceptional items) at Rs 436 Cr
Bengaluru, Karnataka, India: Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the fiscal fourth quarter and the financial year ended March 31, 2026.
FINANCIAL HIGHLIGHTS (CONSOLIDATED): Q4FY26 & Full Year FY26
In Rs Crore
| Particulars | Q4FY26 | Q4FY25 (reported) | Q4 FY25 (adjusted) | YoY (%) | FY26 | FY25 | FY25 | YoY (%) |
| (reported) | (adjusted) | |||||||
| INCOME | ||||||||
| Biosimilars | 2,756 | 2,463 | 2,463 | 12 | 10,431 | 9,017 | 9,017 | 16 |
| Generics | 847 | 1048 | 748 | 13* | 3,168 | 3,017 | 2,717 | 17* |
| CRDMO/ Research Services | 1,037 | 1,018 | 1,018 | 2 | 3,739 | 3,642 | 3,642 | 3 |
| Inter-segment | -122 | -112 | -112 | 9 | -411 | -416 | -416 | -1 |
| Revenue from operations# | 4,517 | 4,417 | 4,117 | 10* | 16,927 | 15,262 | 14,962 | 13* |
| Other income | 53 | 37 | 37 | 42 | 343 | 1,208 | 151 | 1271 |
| Total Income | 4,569 | 4,454 | 4,154 | 10* | 17,270 | 16,470 | 15,113 | 14@ |
| Net R&D Expenses | 277 | 231 | 231 | 20 | 982 | 859 | 859 | 14 |
| EBITDA | 1,073 | 1,115 | 834 | 29* | 3,798 | 4,374 | 3,036 | 25@ |
| EBITDA Margins | 23% | 25% | 20% | 22% | 27% | 20% | ||
| PBT (before Exceptional Items^) | 328 | 466 | 185 | 77* | 851 | 1,790 | 452 | 88@ |
| Net Profit (before Exceptional Items^^) | 179 | 333 | 109 | 64* | 436 | 981 | 103 | 323@ |
| Net Profit (Reported) | 126 | 344 | 120 | 5* | 386 | 1,013 | 135 | 186@ |
Figures above are rounded off to the nearest Crore; % based on absolute numbers.
Leadership Comments
“Biocon closed FY26 on a strong note despite a complex geopolitical environment. We delivered margin expansion along with 13% YoY growth in operating revenue, excluding the one-time impact of generic lenalidomide sales last year. This performance reflects the resilience of our business and disciplined execution through a pivotal year of integration. We have created a unified biopharma entity by integrating biosimilars business with generics formulations and APIs business. The combined business has a stronger balance sheet, improved leverage metrics and a more global commercial footprint. We are now focused on profitability enhancement and long-term value creation.” – Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited
“FY26 was a pivotal year for Biocon, marked by the successful integration of our biosimilars and generics business to create one unified biopharmaceutical enterprise with greater scale, capability, and reach. Even as we integrated the businesses, Biocon delivered ~200 basis points of EBITDA margin expansion at a consolidated level on a like-to-like basis, driven by an improved product mix and operational excellence. Our biosimilars business recorded 16% YoY growth in revenue and 40% increase in EBITDA, on a like-to-like basis. Growth was led by strong performance in advanced markets and key tender wins across emerging markets. With the integration now complete, we shift gears in fiscal 2027 from the “Preserve” phase of our strategy to “Consolidate”, as we set up the business for sustainable growth.”– Shreehas Tambe, CEO & Managing Director, Biocon Limited
“Syngene’s full-year revenue from operations grew 3%, and with an EBITDA margin of 25%, performance was in line with our revised full-year guidance. The overall numbers reflect the specific impact from a single large-molecule biologics client, with the underlying business showing steady momentum. During the year, we continued to invest in new capabilities and emerging modalities such as peptides and ADCs, further strengthening our integrated offering and positioning us for long-term growth.” – Peter Bains, CEO & Managing Director, Syngene International Limited
Leave a Reply